Borderline epithelial tumors of the ovary: Experience of 55 patients

Loizzi, Vera; Selvaggi, Luigi; Leone, Luca; Latorre, Donatella; Scardigno, D.; Magazzino, Francescapaola; Cormio, Gennaro

doi:10.3892/ol.2014.2758

Cited by 22 publications

(26 citation statements)

References 18 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A conservative, fertility-sparing surgery could be considered for patients who wish to preserve fertility [5, 6]. Preoperative imaging, then, can significantly contribute by accurately identifying borderline ovarian tumors, although Medeiros’s studies and our present study showed the difficulty of conventional MRI in differentiating between borderline and malignant tumors [24].…”

Section: Discussionmentioning

confidence: 80%

The value of dynamic contrast–enhanced MRI in characterizing complex ovarian tumors

Qiang

et al. 2017

J Ovarian Res

View full text Add to dashboard Cite

BackgroundThe study aimed to investigate the utility of dynamic contrast enhanced MRI (DCE-MRI) in the differentiation of malignant, borderline, and benign complex ovarian tumors.MethodsDCE-MRI data of 102 consecutive complex ovarian tumors (benign 15, borderline 16, and malignant 71), confirmed by surgery and histopathology, were analyzed retrospectively. The patterns (I, II, and III) of time-signal intensity curve (TIC) and three semi-quantitative parameters, including enhancement amplitude (EA), maximal slope (MS), and time of half rising (THR), were evaluated and compared among benign, borderline, and malignant ovarian tumors. The types of TIC were compared by Pearson Chi-square χ 2 between malignant and benign, borderline tumors. The mean values of EA, MS, and THR were compared using one-way ANOVA or nonparametric Kruskal-Wallis test.ResultsFifty-nine of 71 (83%) malignant tumors showed a type-III TIC; 9 of 16 (56%) borderline tumors showed a type-II TIC, and 10 of 15 (67%) benign tumors showed a type-II TIC, with a statistically significant difference between malignant and benign tumors (P < 0.001) and between malignant and borderline tumors (P < 0.001). MS was significantly higher in malignant tumors than in benign tumors and in borderline than in benign tumors (P < 0.001, P = 0.013, respectively). THR was significantly lower in malignant tumors than in benign tumors and in borderline than in benign tumors (P < 0.001, P = 0.007, respectively). There was no statistically significant difference between malignant and borderline tumors in MS and THR (P = 0.19, 0.153) or among malignant, borderline, and benign tumors in EA (all P > 0.05).ConclusionsDCE-MRI is helpful for characterizing complex ovarian tumors; however, semi-quantitative parameters perform poorly when distinguishing malignant from borderline tumors.

show abstract

Section: Discussionmentioning

confidence: 80%

The value of dynamic contrast–enhanced MRI in characterizing complex ovarian tumors

Qiang

et al. 2017

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…The incidence of BOTs is 1.8–4.8 cases per 100,000 females per year 5. They typically have an excellent prognosis with an overall 10 year survival rate of 83-91% 6,7.…”

Section: Introductionmentioning

confidence: 99%

Borderline tumors of the ovary: A clinicopathological study

et al. 2017

View full text Add to dashboard Cite

Objective:To report experience with borderline ovarian tumors (BOTs) in a developing country like Pakistan with limited resources and weak database of health system.Methods:Patients with BOTs managed at Shaukat Khanum Cancer hospital, Lahore, Pakistan from 2004 to 2014 were included and reviewed retrospectively. Data was recorded on histopathological types, age, CA-125, stage of disease, treatment modalities and outcomes.Results:Eighty-six patients with BOT were included with a median age of 35 years. Forty-two (49%) patients had serous BOTs and 43 (50%) had mucinous BOTs, while one (1%) had mixed type. Using FIGO staging, 80 patients had stage I; two patients had IIA, IIB and stage III each. Median follow-up time was 31.5 months. All patients had primary surgery. Seventy (81%) patients underwent complete surgical resection of tumor. Forty-three (50%) patients had fertility preserving surgery. Seventy-three (85%) patients remained in remission. Recurrent disease was observed in 13 (15%) patients. Median time to recurrence was 22 months. On further analysis, age above forty years, late stage at diagnosis and incomplete surgery were significantly associated with invasive recurrence.Conclusion:Despite a low malignant potential, relapses may occur in patients above forty years of age, incomplete surgery and staging information and advanced stage at presentation. Fertility sparing surgery should be considered in young patients. Complete excision of tumor and prolonged follow-up are advised because recurrence and transformation to invasive carcinoma may occur.

show abstract

“…Borderline serous tumors/atypical proliferative tumor and low-grade serous cancers demonstrate mutations in KRAS or BRAF and few chromosomal abnormalities. High-grade serous carcinomas harbor mutations in TP53 and are chromosomally highly unstable [1,2,3]. …”

Section: Introductionmentioning

confidence: 99%

Prognostic Value of ADAMTS Proteases and Their Substrates in Epithelial Ovarian Cancer

Lima¹,

Santos²,

Turri³

et al. 2016

Pathobiology

View full text Add to dashboard Cite

Background: ADAMTS are metalloproteases with disintegrin and thrombospondin motifs. They are secreted proteases playing a role in biological processes such as inflammation, angiogenesis, and urogenital development. ADAMTS have specific substrates, such as the proteoglycans (PG) versican, aggrecan, and brevican. Despite data indicating a role of ADAMTS in tumor invasion and metastases, effects played by these molecules in cancer progression are still controversial. In ovarian cancer, the importance of ADAMTS gene mutations was recently described and related to chemotherapy outcome. Objective: To analyze protein levels of ADAMTS-1, -4, and -5, and TIMP-3 in human ovarian cancer classified as benign, borderline, or malignant. We also assessed the expression of the ADAMTS substrates aggrecan, brevican, and versican in these neoplasms. Correlations between overall survival and protein expression were performed. Methods: Tumors were classified according to the WHO Classification of Tumors of Female Reproductive Organs. Protein and PG expression was studied by immunohistochemistry. Differences in labeling were analyzed by percent measurements of stained areas. Results: ADAMTS-1, ADAMTS-5, and its tissue inhibitor TIMP-3 are increased in borderline and malignant tumors compared to benign neoplasms. Aggrecan and versican levels were increased in malignant subtypes compared to benign ovarian cancer. Higher ADAMTS-1, TIMP-3, and versican expression was associated with a shorter overall survival. Conclusions: Comparison of protease, TIMP-3, and substrate expression showed that in malignant tumors all ADAMTS and TIMP-3 expression levels were significantly raised compared to the substrates studied.

show abstract

Borderline epithelial tumors of the ovary: Experience of 55 patients

Cited by 22 publications

References 18 publications

The value of dynamic contrast–enhanced MRI in characterizing complex ovarian tumors

The value of dynamic contrast–enhanced MRI in characterizing complex ovarian tumors

Borderline tumors of the ovary: A clinicopathological study

Prognostic Value of ADAMTS Proteases and Their Substrates in Epithelial Ovarian Cancer

Contact Info

Product

Resources

About